» Articles » PMID: 29136207

LinkedOmics: Analyzing Multi-omics Data Within and Across 32 Cancer Types

Overview
Specialty Biochemistry
Date 2017 Nov 15
PMID 29136207
Citations 1206
Authors
Affiliations
Soon will be listed here.
Abstract

The LinkedOmics database contains multi-omics data and clinical data for 32 cancer types and a total of 11 158 patients from The Cancer Genome Atlas (TCGA) project. It is also the first multi-omics database that integrates mass spectrometry (MS)-based global proteomics data generated by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) on selected TCGA tumor samples. In total, LinkedOmics has more than a billion data points. To allow comprehensive analysis of these data, we developed three analysis modules in the LinkedOmics web application. The LinkFinder module allows flexible exploration of associations between a molecular or clinical attribute of interest and all other attributes, providing the opportunity to analyze and visualize associations between billions of attribute pairs for each cancer cohort. The LinkCompare module enables easy comparison of the associations identified by LinkFinder, which is particularly useful in multi-omics and pan-cancer analyses. The LinkInterpreter module transforms identified associations into biological understanding through pathway and network analysis. Using five case studies, we demonstrate that LinkedOmics provides a unique platform for biologists and clinicians to access, analyze and compare cancer multi-omics data within and across tumor types. LinkedOmics is freely available at http://www.linkedomics.org.

Citing Articles

Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma.

Ourailidis I, Stogbauer F, Zhou Y, Beck S, Romanovsky E, Eckert S NPJ Precis Oncol. 2025; 9(1):73.

PMID: 40082664 PMC: 11906922. DOI: 10.1038/s41698-025-00856-2.


A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

Hao Z, An F, Zhang W, Zhu X, Meng S, Zhao B Int J Mol Sci. 2025; 26(5).

PMID: 40076684 PMC: 11899737. DOI: 10.3390/ijms26052061.


RBIS as a prognostic biomarker for progression-free survival in prostate cancer: insights from bioinformatics and immune infiltration analysis.

Chen Z, Fang Y, Zhang J Discov Oncol. 2025; 16(1):297.

PMID: 40069535 PMC: 11896948. DOI: 10.1007/s12672-025-02083-4.


CYP2A6 suppresses hepatocellular carcinoma via inhibiting SRC/Wnt/β-Catenin pathway.

Liu Y, Feng L, Zhang W, Zhang X, Shao L, Zhao X Acta Pharmacol Sin. 2025; .

PMID: 40069491 DOI: 10.1038/s41401-025-01524-8.


MFAP4 is a novel prognostic biomarker in glioma correlating with immunotherapy resistance and ferroptosis.

Lv Y, Gao Y, Di W, Li Z, Shi Y, Hou T Front Pharmacol. 2025; 16:1551863.

PMID: 40061958 PMC: 11885252. DOI: 10.3389/fphar.2025.1551863.


References
1.
Heng Y, Lester S, Tse G, Factor R, Allison K, Collins L . The molecular basis of breast cancer pathological phenotypes. J Pathol. 2016; 241(3):375-391. PMC: 5499709. DOI: 10.1002/path.4847. View

2.
Oh K, Ko E, Kim H, Park A, Moon H, Noh D . Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res. 2011; 13(5):R96. PMC: 3262209. DOI: 10.1186/bcr3034. View

3.
Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z . Proteogenomic characterization of human colon and rectal cancer. Nature. 2014; 513(7518):382-7. PMC: 4249766. DOI: 10.1038/nature13438. View

4.
Fernandez-Banet J, Esposito A, Coffin S, Horvath I, Estrella H, Schefzick S . OASIS: web-based platform for exploring cancer multi-omics data. Nat Methods. 2015; 13(1):9-10. DOI: 10.1038/nmeth.3692. View

5.
. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(7492):315-22. PMC: 3962515. DOI: 10.1038/nature12965. View